EUVIMEDSkopri EUVIMED
Open access · CC BY-NC-ND 4.0

A retrospective audit of the real‐world safety and effectiveness profile of eptinezumab for treatment‐resistant chronic migraine in Australia

Lakshini Gunasekera iD, Shuli Cheng, Emma Foster, Shobi Sivathamboo, Terence O'Brien, Helmut Butzkueven, Jayashri Kulkarni, Elspeth Hutton iD

Headache: The Journal of Head and Face Pain · 2026

DOI: 10.1111/head.70015 ↗

At a glance

Journal article in Headache: The Journal of Head and Face Pain, 2026. Written by Lakshini Gunasekera and 7 co-authors. Institution: Alfred Hospital, Melbourne, Victoria, Australia. Major MEDLINE topics: Antibodies, Monoclonal, Humanized, Migraine Disorders. 23 references. The full text is freely available (open access, CC BY-NC-ND 4.0).

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Objective

To describe the real‐world safety, tolerability, and effectiveness of eptinezumab for chronic migraine prevention in Australia.

Background

Eptinezumab is a relatively new medication for treatment‐resistant chronic migraine prevention. It was only introduced onto the Australian Pharmaceutical Benefits Scheme in August 2023, so there are limited real‐world Australian data regarding its tolerability and effectiveness.

Methods

This is a single center retrospective audit of patients receiving eptinezumab for chronic migraine prevention between 1 September 2023 and 31 December 2024. Headache characteristics were compared at baseline and 3 months after eptinezumab administration. Primary outcomes were mean reductions in monthly headache days (MHD) and monthly migraine days (MMD). Secondary outcomes were mean monthly reductions in acute abortive medications, and adverse events.

Results

Of the 60 patients who received eptinezumab during the study period, a total of 54 patients with complete medical records and headache diaries were used in the statistical analysis. The majority were female (43/54, 80%) with mean age 41.7 years (SD 11.4). Three months after eptinezumab infusion, MMD reduced from 23.0 to 15.4 days ( p value

Subjects

MeSH terms (MEDLINE)

Antibodies, Monoclonal, HumanizedMigraine DisordersHumansFemaleRetrospective StudiesMaleAdultAustraliaMiddle AgedChronic DiseaseTreatment Outcome

Author keywords

calcitonin gene‐related peptideeptinezumabmigraine disorders

Substances

Antibodies, Monoclonal, Humanizedeptinezumab

Authors and institutions

  • Alfred Hospital, Melbourne, Victoria, Australia.
  • Monash University, Melbourne, Victoria, Australia.
  • HER Centre, Melbourne, Victoria, Australia.

ORCID profiles: Lakshini Gunasekera, Elspeth Hutton

Cite

APA

Gunasekera, L., Cheng, S., Foster, E., Sivathamboo, S., O'Brien, T., Butzkueven, H., Kulkarni, J., & Hutton, E. (2026). A retrospective audit of the real‐world safety and effectiveness profile of eptinezumab for treatment‐resistant chronic migraine in Australia. Headache: The Journal of Head and Face Pain. https://doi.org/10.1111/head.70015

Vancouver

Gunasekera L, Cheng S, Foster E, Sivathamboo S, O'Brien T, Butzkueven H, et al. A retrospective audit of the real‐world safety and effectiveness profile of eptinezumab for treatment‐resistant chronic migraine in Australia. Headache: The Journal of Head and Face Pain. 2026. doi:10.1111/head.70015

BibTeX
@article{Gunasekera2026,
  author = {Gunasekera, Lakshini and Cheng, Shuli and Foster, Emma and Sivathamboo, Shobi and O'Brien, Terence and Butzkueven, Helmut and Kulkarni, Jayashri and Hutton, Elspeth},
  title = {A retrospective audit of the real‐world safety and effectiveness profile of eptinezumab for treatment‐resistant chronic migraine in Australia},
  journal = {Headache: The Journal of Head and Face Pain},
  year = {2026},
  doi = {10.1111/head.70015}
}
Start for free →